H. Mann

发表

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

M. Ahn, T. Mok, Yi-long Wu, 2017, The New England journal of medicine.

Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN Trial.

J. Heymach, T. Mitsudomi, D. Harpole, 2021, Clinical lung cancer.

Utility values in health technology assessments: a statistician's perspective

C. Watkins, H. Mann, C. Whately-Smith, 2014, Pharmaceutical statistics.

Pharmacokinetic Study of Osimertinib in Cancer Patients with Mild or Moderate Hepatic Impairment

Karen So, S. Ramalingam, E. Grande, 2019, The Journal of Pharmacology and Experimental Therapeutics.

ADAURA: Phase III, Double‐blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation‐positive Early‐stage NSCLC After Complete Surgical Resection

M. Tsuboi, R. Herbst, Yi-long Wu, 2018, Clinical lung cancer.

Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer

M. Cristofanilli, M. Clemons, M. Basik, 2016, Breast Cancer Research and Treatment.

Advanced solid tumors treated with cediranib: comparison of dynamic contrast-enhanced MR imaging and CT as markers of vascular activity.

D. Collins, M. Orton, N. Tunariu, 2012, Radiology.

Assessing the Influence of Subsequent Immunotherapy on Overall Survival in Patients with Unresectable Stage III Non–Small Cell Lung Cancer from the PACIFIC Study

P. Dennis, Yiduo Zhang, M. Ouwens, 2021, Current therapeutic research, clinical and experimental.

Baseline VEGF as a potential predictive biomarker of vandetanib clinical benefit in patients with advanced NSCLC

R. Herbst, J. Heymach, A. Ryan, 2008 .

Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC).

M. Socinski, Keunchil Park, P. Dennis, 2021, Clinical lung cancer.

TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer.

M. Ahn, Y. Ohe, H. Saka, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Modulation of Fexofenadine Pharmacokinetics by Osimertinib in Patients With Advanced EGFR‐Mutated Non–Small Cell Lung Cancer

Sang-We Kim, V. Moreno, E. Calvo, 2019, Journal of clinical pharmacology.

Epidermal growth factor receptor (EGFR) immunohistochemistry: Comparison of antibodies (Abs) and cut points to predict benefit from gefitinib in a phase III placebo-controlled study in advanced non-small cell lung cancer (NSCLC)

F. Hirsch, C. Watkins, P. Bunn, 2007 .

PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN

N. Reinmuth, Y. Shrestha, Haiyi Jiang, 2019, Annals of Oncology.

Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer

D. Matei, J. Ledermann, C. Scott, 2016, British Journal of Cancer.

Patient-Reported Symptoms and Impact of Treatment With Osimertinib Versus Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The AURA3 Trial.

S. Novello, Chee Khoon Lee, H. Mann, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

D. Planchard, C. Faivre-Finn, S. Senan, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II randomized study of the EGFR, HER2, HER3 signaling inhibitor AZD8931 in combination with anastrozole (A) in women with endocrine therapy (ET) naive advanced breast cancer (MINT).

M. Cristofanilli, M. Clemons, M. Basik, 2013 .

NEPTUNE: Phase III Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC.

Ying Cheng, K. Syrigos, N. Rizvi, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis.

M. Ahn, T. Mok, F. Shepherd, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Association between immune-mediated adverse events and efficacy in metastatic non-small-cell lung cancer patients treated with durvalumab and tremelimumab

N. Shire, Diansong Zhou, H. Kluger, 2022, Frontiers in Immunology.

EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).

R. Ferris, T. Ciuleanu, B. Keam, 2019, Journal of Clinical Oncology.

Baseline Vascular Endothelial Growth Factor Concentration as a Potential Predictive Marker of Benefit from Vandetanib in Non–Small Cell Lung Cancer

R. Herbst, A. Ryan, H. Mann, 2009, Clinical Cancer Research.

Addressing the Impact of the COVID-19 Pandemic on Survival Outcomes in Randomized Phase III Oncology Trials

Binbing Yu, H. Mann, S. Ghiorghiu, 2022, Journal of Data Science.

Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety.

K. Gelmon, S. Domchek, U. Matulonis, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study.

R. Ferris, T. Ciuleanu, B. Keam, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy.

Ayala Hubert, Helen Mann, Gillian Mitchell, 2016, Gynecologic oncology.

Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: A multi-study sub-analysis

S. Domchek, U. Matulonis, S. Kaye, 2015 .

POLO: A randomized phase III trial of olaparib tablets in patients with metastatic pancreatic cancer (mPC) and a germline BRCA1/2 mutation (gBRCAm) who have not progressed following first-line chemotherapy.

H. Kindler, G. Locker, H. Mann, 2015 .

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.

Chia-Chi Lin, Tomonori Hirashima, Helen Mann, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer.

Thomas John, Aleksandra, Aleksandra Markovets, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment patterns and overall survival in metastatic urothelial carcinoma in a real-world, US setting.

J. Simeone, H. Mann, B. Nordstrom, 2019, Cancer epidemiology.

Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI

T. Mitsudomi, T. Mok, J. Yang, 2017, Clinical Drug Investigation.

Study Design and Rationale for a Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Selumetinib in Combination With Docetaxel as Second-Line Treatment in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer (SELECT-1).

P. Jänne, H. Mann, D. Ghiorghiu, 2016, Clinical lung cancer.

Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer

P. Jänne, A. Shaw, L. Crinò, 2015, British Journal of Cancer.

Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT)

G. Schwartz, P. Nathan, R. Carvajal, 2015, BMC Cancer.

Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN

H. Mann, M. Hochmair, L. Havel, 2022, ESMO open.

Exploring intra- and inter-reader variability in uni-dimensional, bi-dimensional, and volumetric measurements of solid tumors on CT scans reconstructed at different slice intervals.

Binsheng Zhao, Yongqiang Tan, Pingzhen Guo, 2013, European journal of radiology.

Assessing the effect of CT slice interval on unidimensional, bidimensional and volumetric measurements of solid tumours

Lawrence H. Schwartz, Binsheng Zhao, Yongqiang Tan, 2012, Cancer imaging : the official publication of the International Cancer Imaging Society.

Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy

D. Matei, J. Ledermann, C. Scott, 2018, British Journal of Cancer.

Osimertinib in patients with T790M mutation‐positive, advanced non–small cell lung cancer: Long‐term follow‐up from a pooled analysis of 2 phase 2 studies

P. Jänne, L. Sequist, T. Mitsudomi, 2018, Cancer.

Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.

T. Mitsudomi, F. Shepherd, L. Crinò, 2016, The Lancet. Oncology.

Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial

S. Senan, Y. Wu, H. Mann, 2022, ESMO open.

Overall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI)

M. Ahn, T. Mok, F. Shepherd, 2019, Annals of Oncology.

85O_PRPatient-reported symptoms and impact of treatment with osimertinib vs chemotherapy for advanced non-small cell lung cancer

T. Mok, S. Novello, A. Templeton, 2017 .

93TiP MERMAID-2: Phase III study of durvalumab in patients with resected, stage II-III NSCLC who become MRD+ after curative-intent therapy

M. Tsuboi, C. Swanton, M. Ahn, 2021 .

NEPTUNE China cohort: First-line durvalumab plus tremelimumab in Chinese patients with metastatic non-small-cell lung cancer.

N. Shire, Jian-hua Chang, Si Sun, 2023, Lung cancer.

Population pharmacokinetic modelling of tremelimumab in patients with advanced solid tumours and the impact of disease status on time‐varying clearance

D. Planchard, Y. Chia, L. Krug, 2022, British journal of clinical pharmacology.

P-347 A phase 3, randomized, double-blind, placebo-controlled study of transarterial chemoembolization combined with durvalumab or durvalumab plus bevacizumab therapy in patients with locoregional hepatocellular carcinoma: EMERALD-1

M. Kudo, R. Lencioni, B. Sangro, 2020 .

A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma (HCC) who are at high risk of recurrence after curative hepatic resection.

R. Lencioni, J. Knox, N. Kokudo, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

331TiPOLYMPIA, NEO-OLYMPIA AND OLYMPIAD: RANDOMIZED PHASE III TRIALS OF OLAPARIB IN PATIENTS (PTS) WITH BREAST CANCER (BC) AND A GERMLINE BRCA1/2 MUTATION (GBRCAM).

P. Fasching, A. Tutt, J. Garber, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Osimertinib versus Standard of Care EGFR TKI as First‐Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset

Ying Cheng, Y. Ohe, E. Cho, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Epidermal growth factor receptor immunohistochemistry

F. Hirsch, C. Watkins, P. Bunn, 2008, Cancer.

Molecular biomarkers to identify patients (pts) who may benefit from durvalumab (D; anti-PD-L1) ± tremelimumab (T; anti-CTLA-4) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) from HAWK and CONDOR studies.

A. Matakidou, L. Siu, Z. Ghazoui, 2020 .

Adjusted indirect comparison using propensity score matching of osimertinib to doublet chemotherapy in patients with EGFRm T790M NSCLC who have progressed after EGFR-TKI

T. Mitsudomi, T. Mok, F. Andersohn, 2016 .

G. Schwartz, P. Nathan, R. Carvajal, 2015, BMC Cancer.

LBA6_PROsimertinib vs standard of care (SoC) EGFR-TKI as first-line treatment in patients with EGFR-TKI sensitising mutation (EGFRm) positive advanced non-small cell lung cancer (NSCLC): FLAURA Asian subset

Ying Cheng, Y. Ohe, B. Chewaskulyong, 2017 .

Abstract OT1-1-04: OlympiA, Neo-Olympia and OlympiAD: Randomized phase III trials of olaparib in patients (pts) with breast cancer (BC) and a germlineBRCA1/2mutation (gBRCAm):

P. Fasching, A. Tutt, J. Garber, 2015 .

A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma at high risk of recurrence after curative hepatic resection or ablation: EMERALD-2.

R. Lencioni, J. Knox, N. Kokudo, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

The validation of published utility mapping algorithms: an example of EORTC QLQ-C30 and EQ-5D in non-small cell lung cancer

M. Dyer, H. Mann, A. Hatswell, 2020, Health Economics Review.

3083 AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: Data from Phase II studies

P. Jänne, T. Mitsudomi, M. Ahn, 2015 .

Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-mutant NSCLC: A Post-Hoc Subgroup Analysis from PACIFIC.

Yi-long Wu, C. Faivre-Finn, B. Cho, 2023, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Utility values in health technology assessments: a statistician's perspective

C. Watkins, H. Mann, C. Fletcher, 2014, Pharmaceutical statistics.

Frequency, severity and timing of common adverse events (AEs) with maintenance olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).

D. Matei, J. Ledermann, C. Scott, 2015 .

P1.10-01 Phase 3 Study of Durvalumab Combined with Oleclumab or Monalizumab in Patients with Unresectable Stage III NSCLC (PACIFIC-9)

F. Barlesi, H. Mann, C. Aggarwal, 2022, Journal of Thoracic Oncology.